Trial data examining total events, not just first events, support choosing apixaban over warfarin and holding aspirin while continuing P2Y12 inhibitors.
Most research comparing the efficacy of different antithrombotic strategies for patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) examines the time to a first ischemic or bleeding event as the primary outcome measure. However, these high-risk patients often experience multiple instances of such events, so examining the comparative efficacy of therapeutic regimens to reduce total events is worthwhile.
In a post hoc analysis of the 2-by-2 factorial, randomized, controlled, AUGUSTUS trial (NEJM JW Cardiol Mar 17 2019 and N Engl J Med 2019; 380:1509), the investigators assessed the incidence of total major or clinically relevant nonmajor bleeding events, total ischemic…
Reviewing Author
DisclosuresGrant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians
Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology
Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis
DisclosuresGrant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians
Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology
Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis